ebooks and download videos Search All  Title  Author 
Home / Nonfiction / Medical / Pharmacology

Handbook of Bioequivalence Testing, Second Edition

| £158.27 | €178.00 | Ca$256.78 | Au$253.40
by Sarfaraz K. Niazi
What is this?DRM-PDF | by download   add to wish list
Handbook of Bioequivalence Testing, Second Edition by Sarfaraz K. Niazi

As the generic pharmaceutical industry continues to grow and thrive, so does the need to conduct adequate, efficient bioequivalence studies. In recent years, there have been significant changes to the statistical models for evaluating bioequivalence. In addition, advances in the analytical technology used to detect drug and metabolite levels have made bioequivalence testing more complex. The second edition of Handbook of Bioequivalence Testing has been completely updated to include the most current information available, including new findings in drug delivery and dosage form design and revised worldwide regulatory requirements. New topics include: A historical perspective on generic pharmaceuticals New guidelines governing submissions related to bioequivalency studies, along with therapeutic code classifications Models of noninferiority Biosimilarity of large molecule drugs Bioequivalence of complementary and alternate medicines Bioequivalence of biosimilar therapeutic proteins and monoclonal antibodies New FDA guidelines for bioanalytical method validation Outsourcing and monitoring of bioequivalence studies The cost of generic drugs is rising much faster than in the past, partly because of the increased costs required for approval-including those for bioequivalence testing. There is a dire need to re-examine the science behind this type of testing to reduce the burden of development costs-allowing companies to develop generic drugs faster and at a lower expense. The final chapter explores the future of bioequivalence testing and proposes radical changes in the process of biowaivers. It suggests how the cost of demonstrating bioequivalence can be reduced through intensive analytical investigation and proposes that regulatory agencies reduce the need for bioequivalence studies in humans. Backed by science and updated with the latest research, this book is destined to spark continued debate on the efficacy of the current bioequivalence testing paradigm.

To view this DRM protected ebook on your desktop or laptop you will need to have Adobe Digital Editions installed. It is a free software. We also strongly recommend that you sign up for an AdobeID at the Adobe website. For more details please see FAQ 1&2. To view this ebook on an iPhone, iPad or Android mobile device you will need the Adobe Digital Editions app, or BlueFire Reader or Txtr app. These are free, too. For more details see this article.

SHARE  Share by Email  Share on Facebook  Share on Twitter  Share on Linked In  Share on Delicious
or call in the US toll free 1-888-866-9150 product ID: 729424

Ebook Details
Pages: 1007
Size: 12.4 MB
Publisher: CRC Press
Date published:   2014
ISBN: 9781482226386 (DRM-PDF)

DRM Settings
Copying:not allowed
Printing:not allowed
Read Aloud:  not allowed

This product is listed in the following categories:

Nonfiction > Medical > Pharmacy
Nonfiction > Medical > Pharmacology

This author has products in the following categories:

Nonfiction > Technology > Food Science
Nonfiction > Technology
Nonfiction > Medical > Pharmacology
Nonfiction > Medical > Pharmacy
Nonfiction > Science > Chemistry > Industrial & Technical
Nonfiction > Medical > Biotechnology
Nonfiction > Science > Biotechnology

If you find anything wrong with this product listing, perhaps the description is wrong, the author is incorrect, or it is listed in the wrong category, then please contact us. We will promptly address your feedback.

Submit 5 page SummaryWhat is this?

© 2016